H K Chopra, Tiny Nair, G S Wander, C K Ponde, Saumitra Ray, Dinesh Khullar, Navin C Nanda, Ravi R Kasliwal, D S Rana, Ashok Kirpalani, J P S Sawhney, Praveen Chandra, Yatin Mehta, Viveka Kumar, S Tewari, A K Pancholia, Vijay Kher, Sandeep Bansal, Sanjay Mittal, Praful Kerkar, P K Sahoo, Ramesh Hotchandani, Sunil Prakash, Nagendra Chauhan, Vishal Rastogi, A Jabir, S Shanmugasundaram, Mangesh Tiwaskar, Ajay Sinha, Vittul Gupta, S S Mishra, S N Routray, A K Omar, Onkar C Swami, Aparna Jaswal, Shamsad Alam, Rajeev Passey, Rajeeve Rajput, Justin Paul, Aditya Kapoor, D Prabhakar, Subhash Chandra, Poonam Malhotra, Vivudh Pratap Singh, Manish Bansal, Priyank Shah, Sanjay Jain, Mohan Bhargava, I B Vijayalakshmi, Kiron Varghaese, Dharmender Jain, Anupam Goel, Namrata Gaur, Rohit Tandon, Asha Moorthy, Sheeba George, V K Katyal, R R Mantri, Rahul Mehrotra, Dilip Bhalla, Vinod Mittal, Sarita Rao, Manish Jagia, Harmeet Singh, Surabhi Awasthi, Ameet Sattur, Rekha Mishra, Anand Pandey, Rajeev Chawla, Shalini Jaggi, Blessy Sehgal, Alok Sehgal, Naresh Goel, Ripen Gupta, Samir Kubba, Abhinav Chhabra, Saurabh Bagga, N R Shastry
In India, heart failure (HF) is an important health concern affecting younger age groups than the western population. A limited number of Indian patients receive guideline-directed medical therapy (GDMT). Selective β-1 blockers (BB) are one of the GDMTs in HF and play an important role by decreasing the sympathetic overdrive. The BB reduces heart rate (HR) reverse the adverse cardiac (both ventricular and atrial), vascular, and renovascular remodeling seen in HF. Bisoprolol, a β-1 blocker, has several advantages and can be used across a wide spectrum of HF presentations and in patients with HF and comorbid conditions such as coronary artery disease (CAD), atrial fibrillation (AF), post-myocardial infarction (MI), uncontrolled diabetes, uncontrolled hypertension, and renal impairment...
December 2023: Journal of the Association of Physicians of India